New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

NEXT STORY
Innovation Pharmaceuticals Data from Phase 2 Brilacidin Oral Mucositis (OM) Trial in Head and Neck Cancer Show Notable Reductions in Median Duration of Severe OM and in Number of Unplanned Visits/Hospital Admissions Due to OM
PREV STORY
Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993

MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to ...

author_avatar
NASDAQ Market News

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress

RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior ...

author_avatar
NASDAQ Market News

Conflicting perception of family presence during resuscitation

LOS ANGELES, Oct. 17, 2016 (GLOBE NEWSWIRE) -- A study from St. Barnabas Hospital ...

author_avatar
NASDAQ Market News